趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體
Polyclonal Antibody to Chemokine C-X-C-Motif Receptor 4 (CXCR4)
CD184; Fusin; NPYR; HSY3RR; LAP3; LCR1; LESTR; NPY3R; NPYRL; WHIM; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide-associated protein 3
- 編號(hào)PAA940Ra01
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來(lái)源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 -
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 616 ¥ 1436 ¥ 2052 ¥ 5130 ¥ 20520
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)CXCR4的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別CXCR4。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| PAA940Ra01 | 趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| International Journal of Cancer | Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model [Wiley: source] |
| Plos one | Emodin Suppresses Migration and Invasion through the Modulation of CXCR4 Expression in an Orthotopic Model of Human Hepatocellular Carcinoma [PubMed: PMC3589458] |
| Atherosclerosis | The non-alcoholic fraction of beer increases stromal cell derived factor 1 and the number of circulating endothelial progenitor cells in high cardiovascular risk subjects: A randomized clinical trial [Pubmed:24530788] |
| Pharmacol Rep.? | Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression [Pubmed:25150002] |
| Pharmacological Reports | Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder [PubMed: 26481549] |
| Pharmacological Reports | A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity [Pubmed:27208878] |
| BMC Cancer.? | Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists [pmc:PMC4866076] |
| Frontiers in Bioengineering and Biotechnology | Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison?… [Pubmed:29670878] |
